Floatz logo

IMA401

Refractory Cancer

Immatics Biotechnologies GmbHPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
73/ 100

Competitive context

180 Active assets in the Refractory Cancer cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sugemalimab
Second Affiliated Hospital of Soochow University
Phase 2BB

View all 50 →

Same molecule, other indications

IMA401 is also rated in:

CancerDormant
CC
Indicative ·
46 / 100
View asset →
Solid Tumor, AdultDormant
CC
Indicative ·
46 / 100
View asset →
cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →